Tom Powles

Tom Powles: The ASCO 24 highlight In My Opinion

Tom Powles, Director of Barts Cancer Center, shared on X:

“The ASCO 24 highlight IMO. Currently 3 peri-operative IO approaches: adjuvant, neoadjuvant or both. NADINE tests neoadjuvant vs adjuvant. If +ve and neoadjuvant IO >adjuvant then shorter stronger peri-operative IO maybe better than longer adjuvant/combined approaches(+/- ctDNA)”

Tom Powles: The ASCO 24 highlight In My Opinion

Source: Tom Powles/X

Adjuvant ASCO 24 highlight cancer ctDNA NADINE Neoadjuvant neoadjuvant IO neoadjuvant vs adjuvant OncoDaily Oncology peri-operative IO approaches Tom Powles